SB 5020 – WashingtonStatus: Inactive / Dead
Year Introduced: 2021
Assessing a penalty on unsupported prescription drug price increases to protect the safety, health, and economic well-being of Washington residents. Requires the Health Care Authority to assess a penalty against a drug manufacturer on revenue generated from a price increase on a prescription drug that is not supported by clinical evidence; prohibits manufacturers from withdrawing a drug from the market to avoid paying the penalty.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.